The aetiology of psoriasis: clues provided by benoxaprofen

Twenty-four patients with psoriasis completed a double-blind trial of benoxaprofen for their cutaneous lesions. Six out of thirteen on the active drug showed very marked improvement. It is believed that benoxaprofen acts by interfering with the migration of polymorphs into the skin through inhibition of leukotriene B4 synthesis.